Star Therapeutics Raises $125M in Series B
Star Therapeutics has successfully raised $125M in a Series B at a $600M valuation led by Polaris Partners, venBio Partners.
Company Overview
Star Therapeutics is a HealthTech company headquartered in Cambridge, MA, founded in 2020 with 80+ employees.
Antibody therapies for cancer
Fundraising Details
- Amount Raised: $125M
- Round Type: Series B
- Valuation: $600M
- Date: 2025-09-29
- Investors: Polaris Partners, venBio Partners
About Star Therapeutics
Antibody therapies for cancer The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Cambridge, MA
- Founded: 2020
- Team Size: 80+
- Industry: HealthTech
What This Means
This funding round demonstrates strong investor confidence in Star Therapeutics's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Star Therapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $600M valuation marks an important milestone for Star Therapeutics, positioning the company among notable players in the HealthTech industry.
Looking Ahead
With this new capital, Star Therapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
---
This fundraising news was reported on 2025-09-29. For more information about Star Therapeutics, visit their headquarters at Cambridge, MA.
